Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.983,97
-0,14%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ KemPharm Inc (KMPH) KemPharm Inc (KMPH) Notizie

KMPH

KemPharm (KMPH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KMPH
DataOraFonteTitoloSimboloCompagnia
29/04/202413:49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KMPHKemPharm Inc
10/04/202422:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KMPHKemPharm Inc
10/04/202413:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KMPHKemPharm Inc
09/04/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KMPHKemPharm Inc
03/04/202422:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KMPHKemPharm Inc
01/04/202423:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KMPHKemPharm Inc
30/06/202322:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
26/06/202322:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KMPHKemPharm Inc
15/05/202323:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KMPHKemPharm Inc
15/05/202322:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KMPHKemPharm Inc
17/04/202322:26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KMPHKemPharm Inc
16/03/202311:02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prrn14a)NASDAQ:KMPHKemPharm Inc
15/03/202312:04Edgar (US Regulatory)Proxy Statment - Contested Solicitations (definitive) (defc14a)NASDAQ:KMPHKemPharm Inc
13/03/202321:30Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:KMPHKemPharm Inc
07/03/202323:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KMPHKemPharm Inc
07/03/202323:28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KMPHKemPharm Inc
01/03/202313:43GlobeNewswire Inc.Zevra Therapeutics Begins Trading as ZVRANASDAQ:KMPHKemPharm Inc
28/02/202314:00GlobeNewswire Inc.Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)NASDAQ:KMPHKemPharm Inc
27/02/202322:30GlobeNewswire Inc.Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyNASDAQ:KMPHKemPharm Inc
27/02/202322:11Edgar (US Regulatory)Proxy Statement - Contested Solicitations (preliminary) (prec14a)NASDAQ:KMPHKemPharm Inc
27/02/202313:30GlobeNewswire Inc.Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 ResultsNASDAQ:KMPHKemPharm Inc
24/02/202313:30GlobeNewswire Inc.Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
23/02/202313:30GlobeNewswire Inc.Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
22/02/202314:50GlobeNewswire Inc.CORRECTION – KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
22/02/202313:30GlobeNewswire Inc.KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
31/01/202313:30GlobeNewswire Inc.KemPharm Enhances Senior Management TeamNASDAQ:KMPHKemPharm Inc
24/01/202313:30GlobeNewswire Inc.KemPharm Issues Letter to ShareholdersNASDAQ:KMPHKemPharm Inc
18/01/202313:30GlobeNewswire Inc.KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyNASDAQ:KMPHKemPharm Inc
11/01/202313:30GlobeNewswire Inc.KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development OfficerNASDAQ:KMPHKemPharm Inc
09/01/202312:30GlobeNewswire Inc.KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease CompanyNASDAQ:KMPHKemPharm Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KMPH

La tua Cronologia

UPBT
LOOMBTC
Loom Network
LSE
0P2I
LBNK
BDCCUSDT
Bitica Coin
BIT
P10QA8
Bnp Paribas Issuance
BIT
Q00340
Leonteq Securities
ASX
PKON
Peako
TSXV
TVE
BIT
P1BAR3
BNP Paribas Issuance
NASDAQ
RADN
ASX
PBHN
Pointsbet
ASX
NSTNA
Northern Star Resources
BIT
P1CSP7
BNP Paribas Issuance
ASX
FYI
Freedom Eye
ASX
PPTCD
Perpetual
ASX
PLLDA
Piedmont Lithium
EU
CPINV
Care Property Invest NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network